Medicenna Secures CA$20 Million Investment Boost
Company Announcements

Medicenna Secures CA$20 Million Investment Boost

Medicenna Therapeutics (TSE:MDNA) has released an update.

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, has announced the completion of a CA$20 million investment from RA Capital Management through a private placement. The funds will propel the development of Medicenna’s MDNA11 program and other preclinical initiatives. Despite the investment, the securities involved in the transaction have not been registered under the U.S. Securities Act and are subject to certain restrictions on sale and offer.

For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMedicenna to Present Innovative Cancer Data at Conferences
TipRanks Canadian Auto-Generated NewsdeskMedicenna Reports Promising Results with MDNA11
TipRanks Canadian Auto-Generated NewsdeskMedicenna Announces Breakthroughs in Cancer Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App